Meeting
2014 ASCO Annual Meeting
E7080 (lenvatinib) in addition to best supportive care (BSC) versus BSC alone in third-line or greater nonsquamous, non-small cell lung cancer (NSCLC).
Authors
Libor Havel
3rd Medical Faculty,Charles University,Hospital Bulovka, Praha, Czech Republic
Libor Havel , Jong-Seok Lee , Ki Hyeong Lee , Paolo Bidoli , Joo-Hang Kim , David Ferry , Young-Chul Kim , Gyorgy Losonczy , Nicola Steele , In Sook Woo , Lea Forst , Yi Ma , Mark Joel Shelton , Fabrina Bologna , Brian Huber , Harish P. Dave
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer - Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT01529112
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 8043)
DOI
10.1200/jco.2014.32.15_suppl.8043
Abstract #
8043
Poster Bd #
224
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Final progression-free survival analysis of phase II study with the combination therapy of DFP-14323, protease inhibitor, and low-dose afatinib as first-line therapy for common EGFR mutation–positive NSCLC.
First Author: Hiroshige Yoshioka
Poster
2022 ASCO Annual Meeting
GALLANT-1: Galectin-3 (Gal-3) inhibitor GB1211 plus atezolizumab (atezo) in patients with non–small cell lung cancer (NSCLC)—A randomized, double-blind trial.
First Author: François Ghiringhelli
Poster
2020 ASCO Virtual Scientific Program
Efficacy and safety of alflutinib (AST2818) in patients with T790M mutation-positive NSCLC: A phase IIb multicenter single-arm study.
First Author: Yuankai Shi
Poster
2020 ASCO Virtual Scientific Program
Clinical efficacy and molecular effects of lenvatinib (Len) and letrozole (Let) in hormone receptor-positive (HR+) metastatic breast cancer (MBC).
First Author: Joline Si Jing Lim